Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

2.

Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial

3.

Experts say oncology, primary care coordination necessary for best cancer patient outcomes

4.

Urinary tract cancer prediction models with high sensitivity and specificity

5.

New guidelines for radiation therapy for HPV-associated head and neck cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot